Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Nivolumab has shown a clear clinical advantage in extending disease-free survival compared to standard care (surveillance alone) in the CheckMate-577 trial, with a hazard ratio of 0.67 indicating a significant reduction in the risk of disease recurrence. However, overall survival data is not yet available, which prevents a higher rating.
Cost effectiveness
The cost-effectiveness estimates for nivolumab are within acceptable thresholds for Healthcare resources, with ICERs reported to be less than £20,000 per QALY gained. This indicates a strong economic value proposition for the treatment.
Quality of life
While specific HRQoL data is not detailed, the committee noted that nivolumab is likely to improve quality of life by addressing a high unmet need in patients with residual disease after surgery. The treatment is expected to have positive psychological benefits, although direct evidence of HRQoL improvements is limited.
Supporting Domains
Safety and Adverse Effects
Nivolumab has a generally well-tolerated safety profile, with adverse events comparable to placebo in the CheckMate-577 trial. Serious adverse events are rare due to improved management systems, although some monitoring is still required.
Comparator Selection
The treatment was compared against standard care (surveillance alone), which is appropriate for the patient population. The evidence from the CheckMate-577 trial provides a solid basis for comparison, although the trial’s specific population limits broader applicability.
Patient Population and Subgroups
The trial population is generally representative of the intended patient population, focusing on adults with completely resected oesophageal or gastro-oesophageal junction cancer. However, there are some demographic differences noted between the trial and Healthcare populations.
Care Pathway Integration
Nivolumab can be integrated into existing treatment pathways with manageable adjustments, as it aligns with current clinical practices for patients with residual disease after neoadjuvant chemoradiotherapy.
Resource Use and Cost Implications
The resource implications of nivolumab are manageable, with the treatment expected to provide significant benefits relative to its costs. The commercial arrangement also helps mitigate budget impact concerns.
Evidence Quality and Robustness
The evidence is based on a robust Phase 3 trial (CheckMate-577) with a well-structured design. However, the absence of overall survival data introduces some uncertainty, preventing a higher rating.
Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding the long-term outcomes and the assumption of a ‘cure’ point, the context of high unmet need and the potential benefits of nivolumab support its use. The committee acknowledged these uncertainties but found them manageable.
